Trial reportEuropean journal of nuclear medicine and molecular imaging2019
Lesion detection by [
Trial report in European journal of nuclear medicine and molecular imaging, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 58 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
58 citing papers in PubMed, 1 synthesis or guideline pooled it, 100 citations in OpenAlex.
- Radiopharmaceuticals for PET and SPECT Imaging: A Literature Review over the Last Decade.International journal of molecular sciences · 2022Pooled it
- CAIX-targeted PET/CT in the evaluation of clear cell renal cell carcinoma: a head-to-head comparison with [European journal of nuclear medicine and molecular imaging · 2026Trial
- Prospective pilot study with [European journal of nuclear medicine and molecular imaging · 2026Trial
- Multimodality staging of renal cell carcinoma-pearls & pitfalls.Abdominal radiology (New York) · 2026Review
- Incidental Detection of a CAIX-avid Breast Invasive Ductal Carcinoma on 68 Ga-NY104 PET/CT During Evaluation of a Suspected Renal Mass.Clinical nuclear medicine · 2026Article
- CAIX-targeted radiotracer for diagnosis and monitoring VEGFR-TKI response in clear cell renal cell carcinoma.European journal of nuclear medicine and molecular imaging · 2026Article
- Application of carbonic anhydrase IX-targeted radiopharmaceuticals in the diagnosis and treatment of clear cell renal cell carcinoma (Review).Oncology letters · 2026Review
- Diagnostic Role and Clinical Impact of Zr-Girentuximab PET-CT for the Diagnosis and Treatment of Clear-Cell Renal Cell Carcinoma.Diagnostics (Basel, Switzerland) · 2026Review
- Clinical nuclear medicine applications of zirconium-89 immuno-PET: a comprehensive review from a radiopharmaceutical perspective.EJNMMI radiopharmacy and chemistry · 2026Review
- Article
- Radiopharmaceuticals in Renal Imaging: A Comprehensive Review of Current Applications and Future Prospects.ACS omega · 2026Review
- Review
- Potential Clinical Applications of HyperpolarizedRecent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer · 2026Review
- Carbonic Anhydrase Inhibitors in Oncology.Sub-cellular biochemistry · 2026Review
- Carbonic Anhydrase-IX Is a Specific and Sensitive Theragnostic Target for Imaging and Radioimmunotherapy in Metastatic Colorectal Cancer.Gastro hep advances · 2026Article
- Isoechoic Renal Tumors: A Case Report and Literature Review.Diagnostics (Basel, Switzerland) · 2025Article
- Modified OPTIModel with oligometastatic disease for the prediction of overall survival of patients with renal cell cancer and symptomatic long bone metastases.Journal of bone oncology · 2025Article
- Theranostics 2.0: Target-driven, artificial intelligence-enabled cancer therapy across tumor types.Diagnostic and interventional imaging · 2025Review
- Carbonic anhydrase-9-targeted near-infrared photoimmunotherapy as a theranostic modality for clear cell renal cell carcinoma.International journal of cancer · 2025Article
- Molecular imaging of renal cell carcinomas: ready for prime time.Nature reviews. Urology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors at 10 institutions in 2 countries.
Funding
Abstract
purposeThe main objective of this preliminary analysis of the IMaging PAtients for Cancer drug selecTion (IMPACT)-renal cell cancer (RCC) study is to evaluate the lesion detection of baseline contrast-enhanced CT, [
methodsBetween February 2015 and March 2018, 42 newly diagnosed mccRCC patients with good or intermediate prognosis, eligible for watchful waiting, were included. Patients underwent CT, [
resultsA total of 449 lesions were detected by ≥1 modality (median per patient: 7; ICR 4.25-12.75) of which 42% were in lung, 22% in lymph nodes and 10% in bone. Combined [
conclusionsThe addition of [
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.